Login Register Cart 0
Generic placeholder image

Current Chromatography

Editor-in-Chief

ISSN (Print): 2213-2406
ISSN (Online): 2213-2414

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Simultaneous Determination of Prasugrel and its Process Related Impurities and Degradation Products in Bulk Drug Substances by RPLC-UV

Author(s): Nayan S. Gadhari, Suyog S. Patil, Jayram V. Gholave, Amol V. Pansare, Viswanath R. Patil* and Sharad S. Upadhyay*

Volume 9, Issue 1, 2022

Published on: 01 April, 2022

Article ID: e170122200262 Pages: 10

DOI: 10.2174/2213240609666220117101725

Price: $65

Abstract

Aims: This study aims to determine the quantitative prasugrel (PG) and its all possible process-related impurities.

Background: To the best of our knowledge, very few analytical methods are available in the literature for monitoring process related impurities and degradation products of PG in bulk drug substance/ active pharmaceutical ingredient (API).

Objective: The objective of this study is the separation of Prasugrel and its all possible process-related impurities viz., desacetyl prasugrel-tautomeric forms, intermediates including desacetyl impurity existing in its keto-enol form and positional tautomer impurities with degradation products.

Methods: A simple and robust HPLC-UV method having Zorbax XDB C18 column (15 cm x 4.6 mm) 3.5μm particle size column was used.

Results: Prasugrel and its process related impurities were separated as well as analyzed in pharmaceutical samples' biological matrices.

Conclusion: RP-LC method was developed for quantitative determination of PG and related substantial impurities were found to be highly specific, sensitive and precise. The major oxidative degradant was identified as PG desacetyl IMPs (keto-enol and positional tautomer) and hydroxyl IMP.

Keywords: Prasugrel, process-related impurities, force degradation study, desacetyl prasugrel-tautomeric forms, pharmacopeia, thiolactone metabolite.

Graphical Abstract

[1]
Rao, N.R.; Kiran, S.S.M.; Prasanthi, N. Pharmaceutical impurities: an overview. Indian J. Pharm. Edu. Res., 2010, 44(3), 301-310.
[2]
Gholave, J.V.; Gadhari, N.S.; Patil, S.S.; Upadhyay, S.S.; Patil, V.R.; Shelke, K.F. Development and validation of a stability-indicating RP-HPLC method for the simultaneous determination of telmisartan and its related substances in telmisartan bulk drug substance. Anal. Chem. Lett., 2020, 10(5), 577-589.
[http://dx.doi.org/10.1080/22297928.2020.1850348]
[3]
International conference on harmonization (ICH) guidelines. Q3A (R2): Impurities in New Drug Substances, 2008.
[4]
Argentine, M.D.; Owens, P.K.; Olsen, B.A. Strategies for the investigation and control of process-related impurities in drug substances. Adv. Drug Deliv. Rev., 2007, 59(1), 12-28.
[http://dx.doi.org/10.1016/j.addr.2006.10.005] [PMID: 17189658]
[5]
Riley, A.B.; Tafreshi, M.J.; Haber, S.L. Prasugrel: A novel antiplatelet agent. Am. J. Health Syst. Pharm., 2008, 65(11), 1019-1028.
[http://dx.doi.org/10.2146/ajhp070496] [PMID: 18499874]
[6]
Clemmensen, P.; Dridi, N.P.; Holmvang, L. Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology. Cardiovasc. Drugs Ther., 2013, 27(3), 239-245.
[http://dx.doi.org/10.1007/s10557-013-6444-2] [PMID: 23380983]
[7]
Farid, N.A.; Smith, R.L.; Gillespie, T.A.; Rash, T.J.; Blair, P.E.; Kurihara, A.; Goldberg, M.J. The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab. Dispos., 2007, 35(7), 1096-1104.
[http://dx.doi.org/10.1124/dmd.106.014522] [PMID: 17403916]
[8]
Anumula, R.R.; Gilla, G.; Aalla, S.; Metil, D.S.; Kurella, S.; Charagondla, K. Preparation of prasugrel hydrochloride. Patent WO2012018791, 2012.
[9]
Moon, M.J.; Oren, P.L. Article of manufacture for prasugrel. Patent US20100179184, 2010.
[10]
Pan, X.; Huang, R.; Zhang, J.; Ding, L.; Li, W.; Zhang, Q.; Liu, F. Efficient synthesis of prasugrel, a novel P2Y12 receptor inhibitor. Tetrahedron Lett., 2012, 53(40), 5364-5366.
[http://dx.doi.org/10.1016/j.tetlet.2012.07.071]
[11]
ALOthman, Z. A; Badjah, A.Y; Alsheetan, K. M; Suhail, M; Ali, I. Enantiomeric resolution of quinolones on crown ether CSP: Thermodynamics, chiral discrimination mechanism and application in biological samples. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2021, 1166, 12250.
[http://dx.doi.org/10.1016/j.jchromb.2021.122550] [PMID: 33545563]
[12]
Ali, I.; Al-Othman, Z.A.; Al-Warthan, A.; Aboul-Enein, H.Y. Recent trends in chiral separations by nano liquid chromatography and nano capillary electrophoresis. Curr. Chromatogr., 2014, 1(2), 81-89.
[http://dx.doi.org/10.2174/2213240601666140301001948]
[13]
Ali, I.; Al-Othman, Z.A.; Al-Warthan, A.; Asnin, L.; Chudinov, A. Advances in chiral separations of small peptides by capillary electrophoresis and chromatography. J. Sep. Sci., 2014, 37(18), 2447-2466.
[http://dx.doi.org/10.1002/jssc.201400587] [PMID: 25044566]
[14]
Ali, I.; Naim, L.; Ghanem, A.; Aboul-Enein, H.Y. Chiral separations of piperidine-2,6-dione analogues on Chiralpak IA and Chiralpak IB columns by using HPLC. Talanta, 2006, 69(4), 1013-1017.
[http://dx.doi.org/10.1016/j.talanta.2005.12.004] [PMID: 18970673]
[15]
Aboul-Enein, H.Y.; Ali, I. Comparative study of the enantiomeric resolution of chiral antifungal drugs econazole, miconazole and sulconazole by HPLC on various cellulose chiral columns in normal phase mode. J. Pharm. Biomed. Anal., 2002, 27(3-4), 441-446.
[http://dx.doi.org/10.1016/S0731-7085(01)00575-1] [PMID: 11755745]
[16]
Wickremsinhe, E.R.; Tian, Y.; Ruterbories, K.J.; Verburg, E.M.; Weerakkody, G.J.; Kurihara, A.; Farid, N.A. Stereoselective metabolism of prasugrel in humans using a novel chiral liquid chromatography-tandem mass spectrometry method. Drug Metab. Dispos., 2007, 35(6), 917-921.
[http://dx.doi.org/10.1124/dmd.106.014530] [PMID: 17353347]
[17]
Farid, N.A.; McIntosh, M.; Garofolo, F.; Wong, E.; Shwajch, A.; Kennedy, M.; Young, M.; Sarkar, P.; Kawabata, K.; Takahashi, M.; Pang, H. Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom., 2007, 21(2), 169-179.
[http://dx.doi.org/10.1002/rcm.2813] [PMID: 17154350]
[18]
Dansette, P.M.; Rosi, J.; Debernardi, J.; Bertho, G.; Mansuy, D. Metabolic activation of prasugrel: Nature of the two competitive pathways resulting in the opening of its thiophene ring. Chem. Res. Toxicol., 2012, 25(5), 1058-1065.
[http://dx.doi.org/10.1021/tx3000279] [PMID: 22482514]
[19]
Dansette, P.M.; Levent, D.; Hessani, A.; Bertho, G.; Mansuy, D. Thiolactone sulfoxides as new reactive metabolites acting as bis- electrophiles: Implication in clopidogrel and prasugrel bioactivation. Chem. Res. Toxicol., 2013, 26(5), 794-802.
[http://dx.doi.org/10.1021/tx400083b] [PMID: 23527615]
[20]
Jayaraman, V.; Balaji, S.K.; Dixit, S.; Kadia, J. Improved method for quantitative determination of prasugrel hydrochloride. Patent WO2013024399, 2013.
[21]
Malati, V.; Raghupatireddy, A.; Mukkanti, K.; Suryanarayana, M.V. Identification of prasugrel (An antiplatelet drug) impurities by LC-MS/MS, rapid determination of prasugrel hydrochloride-related substances, and degradation products in active pharmaceutical ingredient and pharmaceutical dosage forms by stability indicating ultraperformance liquid chromatographic method. J. Liq. Chromatogr. Relat. Technol., 2013, 36(1), 61-79.
[http://dx.doi.org/10.1080/10826076.2011.644052]
[22]
Baertschi, S.W.; Maxwell-Backer, L.; Clemens, M.; Smitka, T.A.; Draper, J.R.; Taylor, K.W.; Kaerner, A.; Jansen, P.J. The degradation chemistry of prasugrel hydrochloride: Part 1-drug substance. J. Pharm. Sci., 2019, 108(9), 2842-2857.
[http://dx.doi.org/10.1016/j.xphs.2019.04.008] [PMID: 30981754]
[23]
Modi, V.J.; Pingale, P.L. Development and validation of analytical method for estimation of prasugrel hydrochloride in bulk and in pharmaceutical formulations. Int. J. Pharm. Bio Sci., 2012, 3(4), 292-298.
[24]
Sriram, V.; Sriram, K.; Angirekula, J.; Tripathi, U.M.; Nayakanti, D. Development and validation of reverse phase hplc method for the determination of impurities in prasugrel hydrochloride. Int. J. Pharm. Tech. Res., 2012, 4, 1407-1416.
[25]
Jhansi, T.N.; Kumar, J.D.; Rao, G.N.; Raju, R.N. Development and validation of stability indicating RP-HPLC method for prasugrel hydrochloride. J. Pharm. Sci., 2020, 9, 1085-1110.
[26]
Arar, S.; Sweidan, K.; Qasem, S. Identification and characterization of the degradation products of prasugrel hydrochloride tablets using LC-MS technique. J. Liq. Chromatogr. Relat. Technol., 2018, 41(1), 14-23.
[http://dx.doi.org/10.1080/10826076.2017.1409238]
[27]
Pulla, R.P.; Sastry, B.S.; Prasad, Y.R.; Raju, N.A. Estimation of prasugrel in tablet dosage form by RP-HPLC. Int. J. Chemtech Res., 2011, 2(3), 34-36.
[28]
Seerapu, R.K.R.; Rao, V.A.; Lavanya, P.; Kumar, P.A.D.; Krishna, R.K.; Reddy, P.V.S. Development of validated RP-HPLC method for the estimation of prasugrel HCl in pure and pharmaceutical formulations. J. Pharm. Res., 2011, 4(9), 3105-3107.
[29]
Sahu, K.; Karthikeyan, C.; Moorthy, N.S.H.N.; Trivedi, P. Comparative study of forced degradation behavior of prasugrel by UPLC and HPLC and the development of validated stability indicating assay method. J. Liq. Chromatogr. Relat. Technol., 2011, 34, 1870-1884.
[http://dx.doi.org/10.1080/10826076.2011.582209]
[30]
Parmar, S.J.; Patel, B.A.; Jain, A.P. Development and validation of RP-HPLC method for prasugrel. J. Chem. Pharm. Res., 2012, 4, 3373-3376.
[31]
Jain, D.K.; Jain, N.; Verma, J. RP-HPLC method for simultaneous estimation of aspirin and prasugrel in binary combination. Int. J. Pharm. Sci. Drug Res., 2012, 4(3), 218-221.
[32]
Prabahar, A.E.; Rao, N.R.; Rao, K.R.S.S.; Kumar, P.V. Method development and validation for the HPLC potency assay of prasugrel tablets. J. Pharm. Res., 2011, 4, 980-982.
[33]
Konari, S.N.; Jacob, J.T. Development and validation of RP-HPLC method for the simultaneous estimation of prasugrel and aspirin in bulk and pharmaceutical dosage form. Inventi. Impact Pharm. Anal. Qual. Assur., 2013, 1, 71-74.
[34]
Srikanth, I.; Sharmila, P.; Bharathi, K.V.; Raju, M.; Naik, M.L.; Nagarjuna, K.A. validated reverse phase HPLC method for the estimation of prasugrel hydrochloride in pharmaceutical dosage forms. J. Innov. Trends Pharm. Sci., 2011, 2, 140-148.
[35]
Ahirrao, V.K.; Patil, C.S.; Bembalkar, S.B.; Ubale, S.B.; Marathe, R.P.; Nawale, R.B.; Landge, M.G.; Pawar, R.P. Stability-indicating LC method for the determination of prasugrel hydrochloride in pharmaceutical dosage form. Sci. Pharm., 2012, 80(2), 379-391.
[http://dx.doi.org/10.3797/scipharm.1201-05] [PMID: 22896824]
[36]
Bhavani, V.; Jameelunnisa, B.; Prakash, M.; Siva, R.T. Stability indicating RP-UPLC method for the estimation of prasugrel HCl in pharmaceutical formulations. Int. J. Biol. Pharm. Allied Sci., 2012, 1, 946-956.
[37]
Patel, S.M.; Patel, C.N.; Patel, V.B. Stability-indicating HPLC method for simultaneous determination of aspirin and prasugrel. Indian J. Pharm. Sci., 2013, 75(4), 413-419.
[http://dx.doi.org/10.4103/0250-474X.119816] [PMID: 24302795]
[38]
COE. European Pharmacopoeia (Ph. Eur.), 10th Edition; EDQM: Strasbourg, France, 2019. Available from: https://www.edqm.eu/en/european-pharmacopoeia-ph-eur-10th-edition
[39]
The United States Pharmacopeial. US Pharmacopeial Convention:. Rockville, MD, 2019.
[40]
Remko, M.; Remková, A.; Broer, R. comparative study of molecular structure, pka, lipophilicity, solubility, absorption and polar surface area of some antiplatelet drugs. Int. J. Mol. Sci., 2016, 17(3), 388.
[http://dx.doi.org/10.3390/ijms17030388] [PMID: 27007371]
[41]
Konermann, L. Addressing a common misconception: ammonium acetate as neutral pH “buffer” for native electrospray mass spectrometry. J. Am. Soc. Mass Spectrom., 2017, 28(9), 1827-1835.
[http://dx.doi.org/10.1007/s13361-017-1739-3] [PMID: 28710594]
[42]
Shinde, Y.; Gawali, S.S. Reversed phase chromatographic separation and isolation of tautomers of naphthoquinoneoximes by hplc effect of pH of mobile phase on separation of 3-chloro-2-hydroxy4-naphthoquinone-1-oxime. J. Anal. Chem., 2014, 69, 1171-1178.
[http://dx.doi.org/10.1134/S1061934814120144]
[43]
Dolan, J.W. Gradient elution, part V: baseline drift problems. LC GC N. Am., 2013, 31(7), 538-543.
[44]
ICH Q2 (R1) Validation of analytical procedures: Text and methodologies. In: International Conference on Harmonization, 2005.

Rights & Permissions Print Cite
Article Metrics
5
© 2024 Bentham Science Publishers | Privacy Policy